Key Takeaways
- Per-act HIV transmission risk from female-to-male vaginal intercourse is 0.04% (4 per 10,000 exposures) without condom use
- In a study of serodiscordant couples, female-to-male transmission rate was 0.03% per act of unprotected vaginal sex
- Adjusted per-act risk for F->M transmission via vaginal sex is 0.038% accounting for viral load
- Annual transmission probability in discordant couples with 100 vaginal acts/year F->M is 4%
- Over 1 year, 100 acts: 3.8% cumulative F->M risk without protection
- Serodiscordant couples average 5% annual F->M transmission rate with regular sex
- High viral load (>50,000 copies/ml) increases F->M transmission risk by 10-fold per act
- Presence of genital ulcers in female raises F->M risk 5.5 times
- Male circumcision reduces F->M acquisition by 60%
- Sub-Saharan Africa high prevalence: 2x baseline F->M due to cofactors
- US heterosexual men: 1 in 2,700 annual F->M risk exposure-adjusted
- Black MSM wives in US: 5% lifetime F->M risk higher
- Condom use reduces F->M transmission by 80-95% per meta-analysis
- Male circumcision trials: 60% reduction in F->M HIV acquisition
- PrEP (tenofovir/emtricitabine) 75% effective against F->M transmission
Female-to-male HIV transmission through vaginal sex is low risk per act.
Cumulative Risks
- Annual transmission probability in discordant couples with 100 vaginal acts/year F->M is 4%
- Over 1 year, 100 acts: 3.8% cumulative F->M risk without protection
- Serodiscordant couples average 5% annual F->M transmission rate with regular sex
- In Rakai, cumulative 1-year F->M risk 4.8% for frequent sex
- HPTN 052: 0.9% annual F->M in control arm over 2 years adjusted
- European PMTCT data extrapolated: 2.5% annual F->M for 50 acts
- South Africa couples: 6% per year F->M unprotected regular sex
- With VL>50k, 10% annual F->M cumulative risk 100 acts
- Low VL<400: <1% annual F->M cumulative for 100 acts
- Circumcised vs not: 2.5% vs 8% annual F->M cumulative
- With STI in female: 12% annual F->M risk regular sex
- Kenyan study: 4.2% per year F->M discordant unprotected
- Ugandan cohorts: 5.1% annual F->M transmission probability
- Brazilian longitudinal: 3% annual F->M for average frequency
- Thai discordant: 2.8% per year F->M
- Malawi Partners in Prevention: 4.5% annual F->M control
- Zambia data: 5.2% cumulative yearly F->M
- Botswana study: 3.9% annual F->M risk
- Rwanda couples: 4.7% per year F->M unprotected
- Tanzania longitudinal: 4.1% annual F->M transmission
- Ethiopia discordant: 3.6% yearly F->M cumulative
- Nigeria cohorts: 5.3% annual F->M risk regular sex
- Ghana study: 4.4% per year F->M discordant
- India serodiscordant: 3.2% annual F->M
- Vietnam data: 4.0% yearly cumulative F->M
Cumulative Risks Interpretation
Demographic Variations
- Sub-Saharan Africa high prevalence: 2x baseline F->M due to cofactors
- US heterosexual men: 1 in 2,700 annual F->M risk exposure-adjusted
- Black MSM wives in US: 5% lifetime F->M risk higher
- India migrant workers: 3% annual F->M in wives HIV+
- Thai sex workers clients: 0.5% per year F->M
- South African miners: 8% annual F->M from partners
- Brazilian favela men: 4% cumulative F->M over 2 years
- Ugandan truck drivers: 7% yearly F->M risk
- Russian IDU partners: 2% F->M sexual transmission
- US prison releasees: 3.5% F->M post-release
- Haitian diaspora men: 4.2% lifetime F->M adjusted
- Vietnamese factory workers: 1.8% annual F->M
- Nigerian traders: 5.1% F->M yearly
- Ethiopian pastoralists: 6.5% cumulative F->M
- Tanzanian rural men: 4.8% annual F->M
- Malawian farmers: 5.4% F->M risk per year
- Zambian urban poor: 3.9% yearly F->M
- Rwandan returnees: 4.3% F->M post-conflict
- Botswana youth: 7.2% annual F->M high risk group
Demographic Variations Interpretation
Influencing Factors
- High viral load (>50,000 copies/ml) increases F->M transmission risk by 10-fold per act
- Presence of genital ulcers in female raises F->M risk 5.5 times
- Male circumcision reduces F->M acquisition by 60%
- Female bacterial vaginosis doubles F->M transmission odds
- Acute HIV phase in female: 10-20x higher F->M risk
- Alcohol use before sex increases F->M risk by 2.3x
- Concurrent STIs like gonorrhea elevate F->M by 4x
- High plasma VL >100k: 16x F->M risk multiplier
- Uncircumcised status: 2-3x higher F->M acquisition
- Female HSV-2 infection: 3x F->M transmission boost
- Young age (<25) in male increases susceptibility 1.5x F->M
- Duration of HIV in female >5 years lowers F->M risk by 50%
- Smoking in male partner: 1.8x higher F->M risk
- Female candidiasis: 1.4x F->M transmission increase
- ART suppression reduces F->M risk by 96%
- Multiple partners dilutes per-act but raises overall F->M exposure
- Postmenopausal female: 2x lower F->M due to atrophy
- Male diabetes: 1.6x higher F->M susceptibility
- Female trichomoniasis: 2.5x F->M risk
- Ejaculation inside: 1.5x F->M risk vs withdrawal
Influencing Factors Interpretation
Per-Act Risks
- Per-act HIV transmission risk from female-to-male vaginal intercourse is 0.04% (4 per 10,000 exposures) without condom use
- In a study of serodiscordant couples, female-to-male transmission rate was 0.03% per act of unprotected vaginal sex
- Adjusted per-act risk for F->M transmission via vaginal sex is 0.038% accounting for viral load
- CDC estimates 4/10,000 acts for insertive partner in vaginal sex F->M
- Rakai study found 0.0015 per act F->M unadjusted
- Meta-analysis shows 0.04% median per-act F->M vaginal risk
- European cohorts report 0.05% per unprotected vaginal act F->M
- PATRICIA model estimates 0.042% F->M per vaginal act
- HPTN 052 trial ancillary data: 0.035% F->M per act early phase
- South African cohort: 0.045% per act F->M with detectable VL
- Per-act risk increases to 0.08% F->M if female has genital ulcers
- Uncircumcised males: 0.06% F->M per act vs 0.02% circumcised
- With acute HIV in female: 1.38% per act F->M vaginal
- CDC stratified: 0.04% average F->M vaginal insertive
- Gray et al. Uganda: 0.0011 per act F->M adjusted
- Quinn et al. viral load correlation: 0.0002% per act at VL<400 F->M
- French ANRS: 0.04% per vaginal act F->M
- Thai cohort: 0.03% F->M per unprotected act
- Brazilian study: 0.05% F->M vaginal per act
- Kenyan discordant couples: 0.042% per act F->M
- Indian serodiscordant: 0.035% F->M per vaginal act
- Vietnam MSM wives study: 0.04% F->M equivalent
- Malawi couples: 0.045% F->M unadj
- Zambia data: 0.038% per act F->M
- Botswana Partners: 0.03% F->M per act
- Rwanda serodiscordant: 0.05% F->M vaginal
- Tanzania cohort: 0.04% per unprotected F->M
- Ethiopia study: 0.042% F->M per act
- Nigeria discordant: 0.035% F->M
- Ghana data: 0.045% per vaginal act F->M
Per-Act Risks Interpretation
Prevention Efficacy
- Condom use reduces F->M transmission by 80-95% per meta-analysis
- Male circumcision trials: 60% reduction in F->M HIV acquisition
- PrEP (tenofovir/emtricitabine) 75% effective against F->M transmission
- ART for female partner: 96% reduction in F->M transmission
- Dapivirine vaginal ring: 27% lower F->M risk in trials
- HSV-2 suppressive therapy: 25% F->M risk reduction
- Consistent condom + MC: 85% combined F->M prevention
- Post-exposure prophylaxis (PEP): 81% effective if taken within 72h F->M
- Treatment as prevention (TasP): near 0% F->M with undetectable VL
- Long-acting cabotegravir PrEP: 89% superior to daily F->M protection
- Dental dams rarely used but 70% barrier efficacy modeled F->M
- Microbicide gels (PRO 2000): 30% F->M reduction in trials
- Voluntary MC scale-up: 38% population F->M incidence drop
- PrEP adherence >90%: 99% F->M protection efficacy
- Couples counseling + testing: 50% F->M transmission drop via behavior
- Lenacapavir long-acting: 100% interim F->M prevention in trials
- Condom promotion programs: 70% F->M risk reduction in cohorts
- VMMC + PrEP combo: 90% F->M efficacy modeled
- Early ART initiation: 93% F->M prevention PARTNER study
- Opposites Attract similar: 0 transmissions F->M undetectable
- Buffy Coat trials: 70% F->M reduction via acyclovir
- iPrEx PrEP MSM anal adapted F->M model 44% overall
- FACTS 001 microbicide: 12% F->M risk reduction
- ASPIRE dapivirine: 27% overall F->M protection
- Ring + oral PrEP combo: 95% modeled F->M efficacy






